Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...
The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...
Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...
As of September 2025, 15 patients have been recruited across 8 centers. Spain, Belgium, and Ireland, with 15 centers, will be open for inclusion in Q4 of 2025, with 9 more centers in France also being ...
Zachary Klaassen hosts Luis Salgado to discuss metastasis-directed therapy for low-volume hormone-sensitive prostate cancer. The conversation highlights the challenge of interpreting disease volume in ...
Biochemical recurrence (BCR) after radical prostatectomy (RP) remains a clinical challenge, with significant heterogeneity in outcomes and optimal management strategies. Salvage radiotherapy (sRT) is ...
At the 2025 UCSF-UCLA PSMA Conference, Thomas Hope challenges using PSMA PET/CT for restaging during radioligand therapy, advocating instead for post-treatment SPECT/CT imaging. While both modalities ...
Login to update email address, newsletter preferences and use bookmarks.
At the 2025 UCSF-UCLA PSMA Conference, Michael Hofman discusses his team's work with Terbium-161 in the VIOLET clinical trial at Peter Mac. He explains Terbium-161 offers both beta and Auger electron ...
Focal therapy (FT) has quickly emerged over the last few decades as a prostate cancer (CaP) treatment option due to the growing research indicating more favorable side effects compared to radical ...
At the 2025 UCSF-UCLA PSMA Conference, Emmanuel Antonarakis compares PSMA radioligand therapy trials in mCRPC for the post-ARPI, pre-chemotherapy setting. He examines PSMAfore (177Lu-PSMA-617), SPLASH ...
At the 2025 UCSF-UCLA PSMA Conference, Daniel Spratt presents on bone scan obsolescence in prostate cancer imaging. He demonstrates they fail to detect cancer with sufficient sensitivity compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results